Press Releases
 |
Webcast
Athenex 2019 SABCS Investor Event and Webcast with Clinical Experts
|
Keyword Search
December 16, 2019
Athenex Expands its Strategic Partnership with Guangzhou Xiangxue Pharmaceutical Through a Licensing Agreement for its Product Candidates Oral Paclitaxel and Oral Irinotecan, as well as Tirbanibulin Ointment, in China, Hong Kong and Macao
The agreement covers China , Hong Kong and Macao (the “Territory”) and represents an expansion of the existing relationship between the two companies. Athenex will receive payments of up to $200 million which include an upfront, development, sales and other milestone payments.
December 13, 2019
Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic Breast Cancer
First oral taxane to demonstrate superior response rate and overall survival compared to IV paclitaxel in a Phase III clinical trial Data to be presented today in an oral presentation at the 2019 San Antonio Breast Cancer Symposium (SABCS) BUFFALO, N.Y. , Dec.
December 11, 2019
Athenex Announces Details of Investor Event and Webcast at SABCS on December 13, 2019
BUFFALO, N.Y. , Dec. 11, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the details for its upcoming event
December 05, 2019
Athenex Announces $60 Million Private Placement
BUFFALO, N.Y. , Dec. 05, 2019 (GLOBE NEWSWIRE) -- Athenex , Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has directly entered into
November 19, 2019
Athenex Announces Key Company Activities at San Antonio Breast Cancer Symposium
Abstract selected for the SABCS press program Oral presentation of Oral Paclitaxel and encequidar Phase III results on December 13 Company to host a Key Opinion Leader webcast event for the investment community BUFFALO, N.Y. , Nov. 19, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc.
November 07, 2019
Athenex, Inc. Announces Third Quarter 2019 Financial Results
Oral presentation of Phase III Oral Paclitaxel data at the San Antonio Breast Cancer Symposium NDA submissions for Oral Paclitaxel and tirbanibulin ointment are on track $19.2 million of product sales in Q3 2019, a 45% year-over-year increase Raising full year 2019 guidance to 35% to 40%
October 30, 2019
Athenex Announces European Commission Grants Orphan Designations for Paclitaxel and Encequidar for the Treatment of Soft Tissue Sarcoma
BUFFALO, N.Y. , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Athenex , Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has received Orphan
October 28, 2019
Athenex Announces Progress Update from Partner Almirall on Tirbanibulin Ointment
BUFFALO, N.Y. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- Athenex , Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced a progress update from partner
October 24, 2019
Athenex Provides An Update to Shareholders
BUFFALO, N.Y. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today provides an update to its shareholders.
October 24, 2019
Athenex, Inc. to Report Third Quarter 2019 Earnings Results on November 7, 2019
BUFFALO, N.Y. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release third quarter
September 23, 2019
Athenex Completes Construction of New API Facility in Chongqing
BUFFALO, N.Y. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has completed construction
September 23, 2019
Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019
BUFFALO, N.Y. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will present several
September 23, 2019
Athenex to Present at the 2019 San Antonio Breast Cancer Symposium
BUFFALO, N.Y. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will be making an oral
September 11, 2019
Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical
BUFFALO, N.Y. , Sept. 11, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that its partner, Guangzhou
September 04, 2019
Athenex Announces Appointment of Daniel Lang MD to Lead TCR-T Immunotherapy Operations and Support Corporate Development Strategy
BUFFALO, N.Y. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Daniel Lang ,
August 07, 2019
Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer
Study met primary endpoint showing statistically significant improvement in overall response rate for oral paclitaxel and encequidar (Oral Paclitaxel) compared to IV paclitaxel based on intention-to-treat (ITT) analysis Strong trend in progression-free survival (PFS) and overall survival (OS) of
August 07, 2019
Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel plus Encequidar and Increased Product Sales Guidance
Positive Phase III results of Oral Paclitaxel show statistically significant improvement in overall response rate in metastatic breast cancer Company is preparing two NDA submissions following successful Phase III studies announced within the last twelve months Expanded clinical pipeline with
August 02, 2019
Athenex Provides an Update Regarding the Vasopressin Case
BUFFALO, N.Y. , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that the U.S.
July 29, 2019
Athenex, Inc. to Report Second Quarter 2019 Earnings Results on August 7, 2019
BUFFALO, N.Y. , July 29, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that it will release second quarter and six-months ended
June 28, 2019
Athenex Announces Strategic Global Initiatives to Expand Clinical Operations
BUFFALO, N.Y. , June 28, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that the Company has strategically expanded its presence
June 24, 2019
Athenex Announces U.S. FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase)
BUFFALO, N.Y. , June 24, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that the U.S.
June 06, 2019
Athenex Provides an Update on its Chongqing API Plant
BUFFALO, N.Y. , June 06, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that its active pharmaceutical ingredient (API) plant in
June 06, 2019
Athenex and PharmaEssentia Announce Positive Early Signals of Clinical Activity of KX2-391 (INN: tirbanibulin) in Patients with Psoriasis
BUFFALO, N.Y. and TAIPEI, Taiwan , June 06, 2019 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, and PharmaEssentia
May 30, 2019
Athenex to Present at the 2019 ASCO Annual Meeting
BUFFALO, N.Y. , May 30, 2019 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will present data and
May 09, 2019
Athenex, Inc. Announces First Quarter 2019 Financial Results and Provides Corporate Update
Positive Phase 3 data for KX2-391 featured at 2019 AAD Annual Meeting Promising early and complete response data reported for Oraxol in cutaneous angiosarcoma Topline results from Oraxol Phase III clinical trial expected August 2019 Presenting four abstracts featuring Athenex product candidates at
May 06, 2019
Athenex Announces $100 Million Private Placement
BUFFALO, N.Y. , May 06, 2019 (GLOBE NEWSWIRE) -- Athenex , Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has directly entered into
May 03, 2019
Athenex Announces Promising Early and Complete Response Data from a Clinical Study of Oraxol in Cutaneous Angiosarcoma
Preliminary data show rapid, visible response to Oraxol monotherapy in the first seven subjects, including three complete responses BUFFALO, N.Y., May 03, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and
April 25, 2019
Athenex, Inc. to Report First Quarter 2019 Earnings Results on May 9, 2019
BUFFALO, N.Y. , April 25, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release first quarter
April 23, 2019
Athenex Announces Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting
BUFFALO, N.Y. , April 23, 2019 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that four abstracts have been
April 02, 2019
Athenex Announces Appointment of John Koh as a New Board Member
BUFFALO, N.Y. , April 02, 2019 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of John Koh as a
March 29, 2019
Athenex Announces Appointment of Jordan S. Kanfer to Board of Directors
Jordan Kanfer to replace SongYi Zhang, J.D., who is stepping down BUFFALO, N.Y. , March 29, 2019 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and
March 28, 2019
Athenex Announces Appointment of Dr. Daniel Von Hoff as Chairman of the Scientific Advisory Board of Axis Therapeutics Limited
BUFFALO, N.Y. , March 28, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Dr.
March 21, 2019
Athenex Announces Xiangxue Life Sciences Receives IND Allowance from China’s National Medical Products Administration for Cancer Immunotherapy Drug Candidate
This company-sponsored IND allows Xiangxue Life Sciences (XLifeSc) to proceed to the next stage of clinical studies in China Encouraging positive clinical safety and efficacy signals were observed in preliminary investigator-initiated pilot studies in China Athenex is XLifeSc’s partner (ex- China )
March 21, 2019
Athenex Announces Expansion of Board of Directors
John Moore Vierling, MD, FACP, FAASLD, AGAF, and Stephanie Davis appointed to the Board of Directors; Sheldon Trainor-De Girolamo resigns from the Board BUFFALO, N.Y. , March 21, 2019 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery,
March 11, 2019
Athenex, Inc. Announces Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update
Oraxol Phase III clinical trial in metastatic breast cancer fully enrolled Positive Phase III topline results of KX2-391 in actinic keratosis featured in late breaker session at recent 2019 AAD Annual Meeting A number of abstracts submitted for presentation at ASCO on six of our products,
March 08, 2019
Athenex to Present Preclinical Data of Oraxol in the Treatment of Angiosarcoma at the American Association for Cancer Research Annual Meeting 2019
BUFFALO, N.Y. , March 08, 2019 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract highlighting the
March 07, 2019
Athenex Regains Rights to KX2-391 in China
BUFFALO, N.Y. , March 07, 2019 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that upon Athenex’s request,
March 04, 2019
Athenex Announces Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting
Results show that 44% and 54% of patients in studies KX01-AK-003 and KX01-AK-004, respectively, achieved 100% AK lesion clearance at Day 57 Safety profile of KX2-391 ointment may be an important competitive advantage ; adherence to treatment was greater than 99% Company to host Conference Call with
February 25, 2019
Athenex to Host Conference Call with Key Opinion Leader Following Oral Presentation of Phase III Results of KX2-391 Ointment in the Treatment of Actinic Keratosis at the American Academy of Dermatology Annual Meeting
Seth B. Forman, MD, CEO of ForCare Medical Group and ForCare Clinical Research, to participate in a call on Monday, March 4, 2019 at 8:30am ET BUFFALO, N.Y. , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development
February 14, 2019
Athenex, Inc. to Report Fourth Quarter and Fiscal Year 2018 Earnings Results on March 11, 2019
BUFFALO, N.Y. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release fourth quarter
February 04, 2019
Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting
Results from Phase III pivotal studies to be featured at Late-Breaking Research Program on March 2, 2019 BUFFALO, N.Y. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel
January 09, 2019
Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study
BUFFALO, N.Y. , Jan. 09, 2019 (GLOBE NEWSWIRE) -- Athenex , Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that target enrollment of 360
January 03, 2019
Chongqing Jingdong Pharmaceutical and Athenex Announce a Strategic Partnership and Licensing Agreement to Develop and Commercialize KX2-391 in China
Chongqing Jingdong Pharmaceutical strengthens its product portfolio of innovative drugs with novel small molecule KX2-391 Athenex further builds its presence in China , broadening global reach Athenex to receive upfront and potential development milestones, along with tiered royalties based on
